Nishikawa Tatsuya, Tamiya Motohiro, Ohta-Ogo Keiko, Ikeda Yoshihiko, Hatakeyama Kinta, Honma Keiichiro, Yasui Taku, Shioyama Wataru, Oka Toru, Inoue Takako, Kumagai Toru, Fujita Masashi
Department of Onco-cardiology, Osaka International Cancer Institute, Osaka, Japan.
Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
CJC Open. 2022 Mar 24;4(7):651-655. doi: 10.1016/j.cjco.2022.03.007. eCollection 2022 Jul.
Immune checkpoint inhibitor (ICI)-related myocarditis has been reported to appear in the early phase after ICI initiation. Herein, we report the case of a 78-year-old man with non-small cell lung cancer. Pembrolizumab was introduced as first-line therapy. After 9 months, second-line therapy, including bevacizumab, was initiated. After another 7 months, echocardiography showed diffuse left ventricular dysfunction. Based on the histopathologic examination of the myocardium, the patient was diagnosed with ICI-related myocarditis. Initiation of prednisolone therapy improved cardiac function. This case of late-onset ICI-related myocarditis illustrates that endomyocardial biopsy can be useful in the differential diagnosis of cancer-related left ventricular dysfunction.
据报道,免疫检查点抑制剂(ICI)相关的心肌炎在ICI开始使用后的早期阶段出现。在此,我们报告一例78岁非小细胞肺癌男性患者的病例。派姆单抗被用作一线治疗。9个月后,开始二线治疗,包括贝伐单抗。又过了7个月,超声心动图显示弥漫性左心室功能障碍。根据心肌的组织病理学检查,该患者被诊断为ICI相关的心肌炎。泼尼松龙治疗的开始改善了心脏功能。这例迟发性ICI相关心肌炎病例表明,心内膜活检在癌症相关左心室功能障碍的鉴别诊断中可能有用。